Thiazole Derivatives Isoform Selective PI3K Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors, such as wortmannin and LY294002, are non-specific and do not distinguish among different PI3K isoforms, making it unclear which isoforms are involved in various cellular responses, including inflammation and cancer, and thus limiting their therapeutic effectiveness.
Innovation Solution
Development of thiazole derivatives that specifically modulate the activity of PI3K α and γ isoforms, providing a new category of pharmaceutical compounds for treating autoimmune, inflammatory, and cardiovascular diseases, among others, by inhibiting the phosphoinositide-3-kinases pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific PI3K inhibitors (wortmannin, LY294002) are used, then broad PI3K pathway inhibition is achieved, but isoform selectivity is lost
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular PI3K isoforms. The thiazole derivatives contain specific substituent patterns (R1-R6 groups) that provide selective binding to PI3Kα and PI3Kγ isoforms, allowing differential inhibition based on local structural characteristics of each isoform's binding site.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters of the inhibitor molecules (substituent types, positions, and configurations in the thiazole core structure) to achieve different levels of isoform selectivity. This allows optimization of the balance between broad pathway inhibition and specific isoform targeting.
2Loss of information
If isoform-specific PI3K inhibitors are developed, then cellular response understanding is improved, but drug development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the PI3K inhibitor development into distinct series targeting different isoforms. The thiazole derivative framework is segmented with specific substituent combinations (e.g., R1=H, R2=specific groups) that confer selectivity for particular isoforms, allowing systematic exploration of structure-activity relationships for each isoform type.
Solution Approach 2:
The patent employs universality by using a common thiazole core structure (Formula I) that can accommodate multiple substituent variations to target different PI3K isoforms. This universal scaffold approach allows a single molecular framework to serve multiple therapeutic purposes by simply changing the R1-R6 substituents, thereby reducing overall development complexity despite targeting multiple isoforms.
3Manufacturing precision
If thiazole derivatives are designed for isoform selectivity, then therapeutic precision is improved, but synthesis complexity increases
Solution Approach 1:
The patent applies preliminary action by pre-establishing the thiazole core structure with key functional groups in place before introducing isoform-specific substituents. The core scaffold is prepared with reactive handles that facilitate subsequent coupling reactions, allowing systematic introduction of R1-R6 groups that confer selectivity without requiring complete de novo synthesis for each isoform-specific compound.
Data Source
AI summary
The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.